Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase II Diabetes Data Heighten Incyte’s Partnership Appeal

This article was originally published in The Pink Sheet Daily

Executive Summary

Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.

You may also be interested in...

No Victory For Victoza: FDA Panel Splits On Whether Cancer Signal Should Block Approval

Liraglutide’s cardiovascular safety profile gets support from a majority of an FDA advisory committee, but a preclinical thyroid cancer risk results in a tied vote on the approvability of Novo Nordisk’s type 2 diabetes drug.

Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis

Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.

Amylin Will Add Pancreatitis Cautions To Byetta Label

FDA issues Medwatch alert warning health care professionals of 30 cases of acute pancreatitis in patients taking the type 2 diabetes drug

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts